ATE198771T1 - Verfahren zur identifizierung von verbindungen zur hemmung von neoplastischen verletzungen - Google Patents

Verfahren zur identifizierung von verbindungen zur hemmung von neoplastischen verletzungen

Info

Publication number
ATE198771T1
ATE198771T1 AT98304247T AT98304247T ATE198771T1 AT E198771 T1 ATE198771 T1 AT E198771T1 AT 98304247 T AT98304247 T AT 98304247T AT 98304247 T AT98304247 T AT 98304247T AT E198771 T1 ATE198771 T1 AT E198771T1
Authority
AT
Austria
Prior art keywords
compound
activity
identifying compounds
cgmp
inhibiting neoplastic
Prior art date
Application number
AT98304247T
Other languages
English (en)
Inventor
Rifat Pamukcu
Gary A Piazza
W Joseph Thompson
Original Assignee
Cell Pathways Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/866,027 external-priority patent/US5858694A/en
Application filed by Cell Pathways Inc filed Critical Cell Pathways Inc
Application granted granted Critical
Publication of ATE198771T1 publication Critical patent/ATE198771T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/533Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving isomerase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98304247T 1997-05-30 1998-05-29 Verfahren zur identifizierung von verbindungen zur hemmung von neoplastischen verletzungen ATE198771T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/866,027 US5858694A (en) 1997-05-30 1997-05-30 Method for identifying compounds for inhibition of cancerous lesions
US4673998A 1998-03-24 1998-03-24

Publications (1)

Publication Number Publication Date
ATE198771T1 true ATE198771T1 (de) 2001-02-15

Family

ID=26724247

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98304247T ATE198771T1 (de) 1997-05-30 1998-05-29 Verfahren zur identifizierung von verbindungen zur hemmung von neoplastischen verletzungen

Country Status (16)

Country Link
US (3) US6500610B1 (de)
EP (2) EP0881300B1 (de)
JP (3) JP3053381B2 (de)
KR (1) KR100304859B1 (de)
AT (1) ATE198771T1 (de)
AU (1) AU709666B2 (de)
CA (1) CA2238283C (de)
CZ (1) CZ295868B6 (de)
DE (2) DE69800488T2 (de)
DK (1) DK0881300T3 (de)
ES (1) ES2132055T3 (de)
HK (1) HK1012196A1 (de)
IL (1) IL124699A (de)
NO (1) NO321717B1 (de)
TR (1) TR199800960A3 (de)
TW (1) TW591111B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009464A1 (en) * 1998-10-15 2004-01-15 Li Liu Methods for identifying compounds for inhibition of neoplastic lesions, and pharmacetical compositions containing such compounds
IL132366A0 (en) * 1998-10-15 2001-03-19 Cell Pathways Inc Methods for identifying compounds for inhibition of neoplastic lesions and pharmaceutical compositions containing such compounds
US20020009764A1 (en) * 1999-10-08 2002-01-24 W. Joseph Thompson Methods for identifying compounds for inhibition of neoplastic lesions, and pharmaceutical compositions containing such compounds
US20050244914A1 (en) * 1999-10-08 2005-11-03 Li Liu Methods for identifying compounds for inhibition of neoplastic lesions, and pharmaceutical compositions containing such compounds
DE10060388A1 (de) * 2000-12-05 2002-06-06 Merck Patent Gmbh Verwendung von Pyrazolo [4,3-d]pyrimidinen
FR2824334B1 (fr) 2001-05-03 2003-10-10 Coletica Procede pour tester une substance eventuellement active dans le domaine de la lipolyse et son utilisation principalement cosmetique
WO2003008578A2 (en) * 2001-07-20 2003-01-30 Board Of Trustees Of The University Of Illinois Reagents and methods for identifying gene targets for treating cancer
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
JP2004536614A (ja) * 2001-08-01 2004-12-09 ユニバーシティ オブ ユタ Pde3環状ヌクレオチド・ホスホジエステラーゼのアイソフォーム選択的な阻害剤および活性化剤
WO2003038430A1 (fr) * 2001-10-29 2003-05-08 Takeda Chemical Industries, Ltd. Technique d'analyse
US20050048573A1 (en) * 2003-02-03 2005-03-03 Plexxikon, Inc. PDE5A crystal structure and uses
US7711584B2 (en) 2003-09-04 2010-05-04 Hartford Fire Insurance Company System for reducing the risk associated with an insured building structure through the incorporation of selected technologies
US7659426B2 (en) 2003-12-01 2010-02-09 Reverse Proteomics Research Institute Co., Ltd. Target protein of anticancer agent and novel anticancer agent (spnal) corresponding thereto
JP2008503446A (ja) * 2004-05-06 2008-02-07 プレキシコン,インコーポレーテッド Pde4b阻害剤及びその使用
CA2583428A1 (en) * 2004-09-03 2006-03-09 Plexxikon, Inc. Bicyclic heteroaryl pde4b inhibitors
EP1838319B1 (de) 2005-01-07 2018-03-07 The Johns Hopkins University Pde5-inhibitor-zusammensetzungen und verfahren für die immuntherapie
WO2006097459A1 (en) * 2005-03-14 2006-09-21 Nycomed Gmbh Method for preventing cardiovascular diseases
WO2007081694A2 (en) * 2006-01-04 2007-07-19 Southern Research Institute Derivatives of sulindac, use thereof and preparation thereof
JP2007224007A (ja) * 2006-03-27 2007-09-06 Univ De Santiago De Compostela yessotoxinsのヒト腫瘍細胞増殖抑制剤としての治療的な使用
US8673914B2 (en) 2011-03-28 2014-03-18 St. John's University Use of phosphodiesterase inhibitors for treating multidrug resistance
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE274218C (de)
GB807826A (en) 1955-03-14 1959-01-21 Thomae Gmbh Dr K Derivatives of pyrimido[5,4-d] pyrimidine and production thereof
US3031450A (en) 1959-04-30 1962-04-24 Thomae Gmbh Dr K Substituted pyrimido-[5, 4-d]-pyrimidines
AT290523B (de) 1962-01-05 1971-06-11 Merck & Co Inc Verfahren zur Herstellung neuer α-(3-Indolyl)-carbonsäuren
US3322755A (en) 1964-03-10 1967-05-30 Boehringer Sohn Ingelheim Basic-substituted 1, 2, 3, 4-tetrahydropyrimido [5, 4-d]-pyrimidines
US3812127A (en) 1966-10-31 1974-05-21 Pfizer 4-(quinolin-4-yl)piperazine-1-carboxylic acid esters
GB1199768A (en) 1966-10-31 1970-07-22 Pfizer & Co C Nitrogen Heterocycles and process for their preparation
US3517005A (en) 1967-10-26 1970-06-23 Pfizer & Co C Certain 2- and 4-substituted quinazolines
US3752826A (en) 1970-01-26 1973-08-14 Mcneilab Inc Aroyl substituted pyrroles
US3647858A (en) 1970-05-01 1972-03-07 Merck & Co Inc Process for preparing 1-benzylidene-3-indenyl acetic acids
US3654349A (en) 1970-05-01 1972-04-04 Merck & Co Inc Substituted indenyl acetic acids
US3819631A (en) 1970-12-15 1974-06-25 May & Baker Ltd Azapurinones
GB1493685A (en) 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
US3780040A (en) 1972-06-02 1973-12-18 R Schnettler 2-substituted-3,4-dihydroquinazolines
JPS4966691A (de) 1972-10-30 1974-06-27
JPS5825980B2 (ja) * 1976-02-12 1983-05-31 ヤマサ醤油株式会社 サイクリックヌクレオチドの定量法
US4060615A (en) 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
US4001237A (en) 1976-02-18 1977-01-04 Bristol-Myers Company Oxazole, isoxazole, thiazole and isothiazole amides
US4001238A (en) 1976-02-18 1977-01-04 Bristol-Myers Company 1,3,4-oxadiazole amides
US4076711A (en) 1976-04-05 1978-02-28 Schering Corporation Triazolo [4,5-d]-pyrimidines
US4101548A (en) 1977-02-22 1978-07-18 Bristol-Myers Company 1,2,3-Thiadiazole amides
US4171363A (en) 1977-02-22 1979-10-16 Bristol-Myers Company 1,2,3-Thiadiazole process
US4079057A (en) 1977-05-31 1978-03-14 Bristol-Myers Company Selective immunosuppressive agents
US4102885A (en) 1977-06-20 1978-07-25 Bristol-Myers Company Process for preparing 2,4-dihaloquinazolines
US4098788A (en) 1977-06-20 1978-07-04 Bristol-Myers Company Process for preparing quinazolines
US4138561A (en) 1977-09-30 1979-02-06 Bristol-Myers Company Cyanocarboxamidines and quinazoline process
US4146718A (en) 1978-04-10 1979-03-27 Bristol-Myers Company Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides
US4209623A (en) 1978-06-07 1980-06-24 Bristol-Myers Company Pyrimidine-5-N-(1H-tetrazol-5-yl)-carboxamides
US4208521A (en) 1978-07-31 1980-06-17 Bristol-Myers Company Process for the preparation of imidazo[2,1-b]quinazolinones
US4161595A (en) 1978-10-02 1979-07-17 Bristol-Myers Company Levulinic acid salt
DE2845766A1 (de) 1978-10-18 1980-04-30 Schering Ag Pyrido eckige klammer auf 2,1-b eckige klammer zu -chinazolinon-derivate, ihre herstellung und verwendung
GB2063249A (en) 1979-10-09 1981-06-03 Mitsubishi Yuka Pharma 4-Phenylphthalazine derivatives
JPS5653659A (en) 1979-10-09 1981-05-13 Mitsubishi Yuka Yakuhin Kk Blood platelet coagulation suppressing agent
US4423075A (en) 1980-06-19 1983-12-27 Ayerst, Mckenna & Harrison Inc. Aldose reductase inhibition by 5-fluoro-2-methyl-1-[[4-(methylsulfonyl)phenyl]methylene]-1H-indene-3-acetic acid
JPS57167974A (en) 1981-04-09 1982-10-16 Mitsubishi Yuka Yakuhin Kk Preparation of 4-phenylphthalazine derivative
DE3131365A1 (de) 1981-08-07 1983-02-24 Henkel KGaA, 4000 Düsseldorf Neue diglycidyl-substituierte heterocyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung in arzneimittelzubereitungen mit cytostatischer wirksamkeit
US5250535A (en) 1982-02-01 1993-10-05 Syntex Inc. Substituted 9-(1 or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl) purines as antiviral agent
US4460591A (en) 1982-08-26 1984-07-17 Sri International 8,10-Dideazaminopterins
FI94133C (fi) * 1985-04-19 1995-07-25 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten griseoliinihapon johdannaisten valmistamiseksi
US4837239A (en) 1985-08-23 1989-06-06 Syntex (U.S.A.) Inc. Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
DE3770095D1 (de) 1986-08-21 1991-06-20 Pfizer Chinazolindione und pyridopyrimidindione.
CA1303037C (en) 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
AU3192289A (en) 1988-02-08 1989-08-25 Schering Corporation Nucleosidetype compounds which are phosphodiesterase inhibitors
US5091431A (en) 1988-02-08 1992-02-25 Schering Corporation Phosphodiesterase inhibitors
US5254571A (en) 1988-04-21 1993-10-19 Smith Kline & French Laboratories Ltd. Chemical compounds
ES2058527T3 (es) 1988-06-16 1994-11-01 Smith Kline French Lab Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
GB8814352D0 (en) 1988-06-16 1988-07-20 Smith Kline French Lab Chemical compounds
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US4923874A (en) 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
US4971972A (en) 1989-03-23 1990-11-20 Schering Corporation Phosphodiesterase inhibitors having an optionally substituted purine derivative portion and a benzo- or cyclopenta-furan portion
GB8909560D0 (en) 1989-04-26 1989-06-14 Smith Kline French Lab Chemical compounds
US5376683A (en) 1989-07-14 1994-12-27 Schering Aktiengesellschaft Δ8- and Δ9-prostaglandin derivatives, process for their production and their pharmaceutical use
GB8923131D0 (en) 1989-10-13 1989-11-29 Smith Kline French Lab Chemical compounds
US5091430A (en) 1990-03-13 1992-02-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services O6 -substituted guanine compounds and methods for depleting O6 -alkylguanine-DNA alkyltransferase levels
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
NZ238609A (en) 1990-06-21 1993-12-23 Schering Corp Polycyclic guanine derivatives; preparation, pharmaceutical compositions,
ZA916646B (en) 1990-08-23 1992-07-29 Synphar Lab Inc Novel isocarbostiryl compounds and anti-tumor use thereof
US5175151A (en) 1990-09-07 1992-12-29 Schering Corporation Antiviral compounds and antihypertensive compounds
AU650689B2 (en) 1990-11-06 1994-06-30 Fgn, Inc. Esters and amides of substituted indenyl acetic acids
AU659106B2 (en) 1990-11-06 1995-05-11 Fgn, Inc. Method for treating colonic polyps by the use of esters and amides of substituted phenyl and pyridyl amino carboxylates
AU659107B2 (en) 1990-11-06 1995-05-11 Fgn, Inc. Method for treating colonic polyps by the use of esters and amides of substituted fused ring phenyl acetic acids
AU650914B2 (en) 1990-11-06 1994-07-07 Fgn, Inc. Esters and amides of substituted phenyl acetic acids
AU658373B2 (en) 1990-11-06 1995-04-13 Fgn, Inc. Esters and amides of substituted pyrrole acetic acids
US5401774A (en) * 1991-03-08 1995-03-28 University Of Arizona Method for treating patients with precancerous lesions by administering substituted sulfonyl idenyl acetic and propionic acids and esters to patients with lesions sensitive to such compounds
AU650720B2 (en) * 1991-03-08 1994-06-30 Fgn, Inc. Method for treating patients with precancerous lesions by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof
DE69212058T2 (de) 1991-03-11 1997-01-09 Kyowa Hakko Kogyo Kk Indol-Derivate
US5223501A (en) 1991-05-10 1993-06-29 Merck & Co., Inc. Substituted pyrimidinones bearing acidic functional groups as angiotensin ii antagonists
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5731167A (en) 1992-01-17 1998-03-24 The United States Of America As Represented By The Department Of Health And Human Services Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy
JP2657760B2 (ja) 1992-07-15 1997-09-24 小野薬品工業株式会社 4−アミノキナゾリン誘導体およびそれを含有する医薬品
AU672224B2 (en) 1992-08-06 1996-09-26 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and whichhave antitumor properties
KR960700338A (ko) 1993-01-29 1996-01-19 우에하라 아키라 환상 뉴클레오티드 분해효소 및 그의 제조법
ATE405291T1 (de) * 1993-06-23 2008-09-15 Peter Leskovar Mittel zur beeinflussung von hyperaktivierten immunologischen effektorzellen
DE4330177A1 (de) 1993-08-31 1995-03-02 Schering Ag Neue 9-Chlor-prostaglandin-derivate
WO1995007267A1 (fr) 1993-09-10 1995-03-16 Eisai Co., Ltd. Compose de quinazoline
EP0738390B1 (de) * 1994-01-06 2003-04-02 Telik, Inc. Surrogate für bindemoleküle und verbesserte referenzpanele
ATE412769T1 (de) * 1994-04-05 2008-11-15 Morre D James Nadh-oxidase als zielmolekül in diagnose und therapie
US5776962A (en) * 1994-08-03 1998-07-07 Cell Pathways, Inc. Lactone compounds for treating patient with precancerous lesions
US5696159A (en) 1994-08-03 1997-12-09 Cell Pathways, Inc. Lactone compounds for treating patients with precancerous lesions
DE19501481A1 (de) 1995-01-19 1996-07-25 Bayer Ag 2,8-Disubstituierte Chinazolinone
US5674876A (en) 1995-01-20 1997-10-07 Research Development Foundation ρ-heteroatom-substituted phenols and uses thereof
US5488055A (en) 1995-03-10 1996-01-30 Sanofi Winthrop Inc. Substituted N-cycloalkylmethyl-1H-pyrazolo(3,4-b)quinolin-4 amines and compositions and methods of use thereof
US5614530A (en) 1995-03-10 1997-03-25 Sterling Winthrop Inc. Substituted N-arylmethyl and heterocyclmethyl-1H-pyrazolo[3,4-b]quinolin-4-amines and compositions and methods of use thereof
DE19518082A1 (de) 1995-05-17 1996-11-21 Merck Patent Gmbh 4(-Arylaminomethylen)-2,4-dihydropyrazol-3-one
US5874440A (en) 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
GB9526245D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526243D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
US5798246A (en) 1996-03-25 1998-08-25 Incyte Pharmaceuticals, Inc. Cyclic nucleotide phosphodiesterase
US6063818A (en) * 1996-06-13 2000-05-16 Cell Pathways Inc. Substituted benzylidene indenyl formamides, acetamides and propionamides
US5998477A (en) * 1996-06-13 1999-12-07 Cell Pathways Inc. Substituted methoxy benzylidene indenyl-acetic and propionic acids for treating patients with precancerous lesions
US6043224A (en) * 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US5869519A (en) 1996-12-16 1999-02-09 Idun Pharmaceuticals, Inc. C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
AU740783B2 (en) 1996-09-18 2001-11-15 Applied Genetics Incorporated Dermatics Pharmaceutical compositions and methods
US5858694A (en) 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
US5932465A (en) 1997-10-16 1999-08-03 Icos Corporation Phosphodiesterase 8A
US5922595A (en) 1997-12-09 1999-07-13 Incyte Pharmaceuticals, Inc. Cyclic GMP phosphodiesterase
US5852035A (en) 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US5942520A (en) 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US6200771B1 (en) * 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6235776B1 (en) * 1998-11-12 2001-05-22 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
US6235782B1 (en) * 1998-11-12 2001-05-22 Rifat Pamukcu Method for treating a patient with neoplasia by treatment with a platinum coordination complex

Also Published As

Publication number Publication date
EP0881300A2 (de) 1998-12-02
EP1038523A2 (de) 2000-09-27
EP1038523A3 (de) 2000-10-25
US20030004093A1 (en) 2003-01-02
CA2238283C (en) 2002-08-20
TR199800960A2 (xx) 1998-12-21
CA2238283A1 (en) 1998-11-30
TR199800960A3 (tr) 1998-12-21
JP2000198746A (ja) 2000-07-18
CZ165198A3 (cs) 1999-01-13
EP0881300A3 (de) 1999-01-20
US20030190686A1 (en) 2003-10-09
ES2132055T1 (es) 1999-08-16
US6500610B1 (en) 2002-12-31
NO982477L (no) 1998-12-01
AU709666B2 (en) 1999-09-02
KR19980087436A (ko) 1998-12-05
IL124699A0 (en) 1998-12-06
ES2132055T3 (es) 2001-05-01
NO982477D0 (no) 1998-05-29
JPH1194823A (ja) 1999-04-09
JP3234818B2 (ja) 2001-12-04
DE69800488T2 (de) 2001-08-09
IL124699A (en) 2003-02-12
NO321717B1 (no) 2006-06-26
JP3053381B2 (ja) 2000-06-19
JP2000028601A (ja) 2000-01-28
AU6979498A (en) 1998-12-10
CZ295868B6 (cs) 2005-11-16
EP0881300B1 (de) 2001-01-17
DE881300T1 (de) 1999-08-19
DE69800488D1 (de) 2001-02-22
HK1012196A1 (en) 1999-07-30
KR100304859B1 (ko) 2001-11-30
TW591111B (en) 2004-06-11
DK0881300T3 (da) 2001-06-18

Similar Documents

Publication Publication Date Title
DE69800488D1 (de) Verfahren zur Identifizierung von Verbindungen zur Hemmung von neoplastischen Verletzungen
ATE217865T1 (de) Verbindungen zur hemmung von phosphodiesrerase iv
DE69531753D1 (de) Verbindungen zur Hemmung der Thrombin
ATE538794T1 (de) Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
DE69435270D1 (de) Verwendung der neurotoxischen Komponente von Botulinum Toxin zur Behandlung spastischer Muskeln
DE60231407D1 (de) Hemmende antikörper der her3-aktivität
GB2409719A (en) Use of distributed temperature sensors during wellbore treatments
WO2002030353A3 (en) NF-λB INHIBITORS
DE69831937D1 (de) Bicyclische protein-farnesyl-transferase inhibitoren
WO2000061167A3 (en) TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS
ZA926837B (en) A pharmaceutical composition for and a method of using a combination of an uricosuric agent and an EAA antagonist
DE69830069D1 (de) Verwendung von hemmern des renin-angiotensin systems zur behandlung von hypoxie oder verringertem stoffwechsel
DE69724350D1 (de) Verfahren zum Erhöhen der Anti-Benetzbarkeit eines Körpers, Körper dementsprechend behandelt.
ATE224915T1 (de) Verwendung einer inhibitorsubstanz zur förderung der neuronalen regeneration
WO2001087239A3 (en) Methods of affecting laminin 5 processing
DE69206316D1 (de) Verfahren zur Metalloberflächenbehandlung mit Zinkphosphat.
DE69703328D1 (de) Wässrige Antirostadditive, Verfahren zur Rostschutzbehandlung und rostschutzbehandelte Metalloberfläche
DE69901082T2 (de) Verfahren zur Identifizierung von Verbindungen zur Hemmung von neoplastischen Veränderungen
DE69630969D1 (de) Verfahren zur hemmung des plasminogen-aktivator-inhibitors
DE69609823D1 (de) Verfahren zur inhibierung der zersetzung von 1,1,1,2,3,3-hexafluorpropan und 1,1,1,3,3-pentafluorpropan und zersetzungsinhibitor
DE50103458D1 (de) Kontinuierliches Verfahren zur Cyanalkylierung von Verbindungen mit einer oder mehreren NH-Funktionen
DE69101911D1 (de) Verfahren und vorrichtung für die biologische reinigung von abwasser einschliesslich der denitrifikation.
DE69808607D1 (de) Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz
DE69525439T2 (de) Antibiotikum und verfahren zu dessen herstellung
WO2004041211A3 (en) INHIBITORS OF β-SECRETASE, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF ALZHEIMER’S DISEASE OR MILD COGNITIVE IMPAIRMENT

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee